BioCentury
ARTICLE | Financial News

Annexon raises $34M in series A-1

December 16, 2014 3:17 AM UTC

Annexon Bioscience raised $34 million in a series A-1 round led by Novartis Venture Fund along with Satter Investment Management and Clarus Ventures. All were new investors. CEO Doug Love told BioCentury the round is "committed," but declined to give further details.

Annexon is developing inhibitors of the complement pathway to treat neurodegenerative and autoimmune diseases. ...